{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-015597","form_type":"8-K","ticker":"ALKS","cik":"0001520262","company_name":"Alkermes plc.","filed_at":"2024-02-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.477570+00:00","generated_at":"2026-06-06T01:10:55.537872+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Alkermes reports 2023 total revenues $1.66B, GAAP EPS $2.10; guides 2024 EBITDA ~$445-485M","bullets":["GAAP net income $355.8M vs loss of $158.3M in 2022; diluted EPS $2.10.","Proprietary net sales $920M (+18% YoY); LYBALVI grew to $191.9M (up 100% YoY).","2024 guidance: total rev $1.5-1.6B, GAAP net income $350-390M, non-GAAP net income $465-505M.","Board approved new $400M share repurchase program (no expiration date).","Oncology separation completed Nov 2023; Athlone facility sale to Novo Nordisk for $92.5M expected mid-2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-015597","json":"https://secwatch.observer/filing/0000950170-24-015597.json","markdown":"https://secwatch.observer/filing/0000950170-24-015597.md","text":"https://secwatch.observer/filing/0000950170-24-015597.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1520262/000095017024015597/0000950170-24-015597-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1520262/000095017024015597/alks-20240215.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T01:10:55.537872+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"dafd759a1786fe523d0a0f94e16fc8fef81f3553","claim":"Alkermes plc. reported the quarter and year ended Dec. 31, 2023 results: revenue $1,663.4 million, net income $355.8 million, EPS $2.10. Guidance initiated.","evidence_excerpt":"Joyce +1 781 249 8927 Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2023 and Provides Financial Expectations for 2024 — Total Revenues of $1.66 Billion in 2023; Net Sales of Proprietary Products Increased Approximately 18% Year-Over-Year — — GAAP Net Income of $356 Million and Diluted GAAP Earnings per Share of $2.10 for 2023 —","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1520262/000095017024015597/0000950170-24-015597-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter and year ended Dec. 31, 2023"},{"label":"Revenue","value":"$1,663.4 million"},{"label":"Net income","value":"$355.8 million"},{"label":"EPS","value":"$2.10"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}